Research Article

Development and in-vitro Evaluation of a Topical Drug Delivery System Containing Betamethazone Loaded Ethyl Cellulose Nanospheres

Kumaraswamy Santhi, Dhandapani Nagasamy Venkatesh*, Sokkalingam Arumugam Dhanaraj, Shanmugasundaram Sangeetha and Bhojraj Suresh
Dept of Pharmaceutics, J S S College of pharmacy, Ooty - 643 001. Tamil Nadu, India.

Abstract

**Purpose:** Lipid nanospheres are used for the passive targeting of cosmetic agents to skin, thereby achieving major benefits such as reduction of total dose and avoidance of systemic absorption. The present study was carried out to exploit the feasibility of using polymeric nanospheres as an alternative and cheaper carrier for targeting corticosteroids to the skin.

**Methods:** Nanospheres were prepared from ethyl cellulose by a modified method of desolvation and cross linking. The drug betamethazone was incorporated into nanospheres and the drug: polymer ratio was evaluated to determine the carrier capacity of the polymer. In vitro release studies of drug-loaded nanospheres were carried out by the centrifugal ultrafiltration method. The kinetics of release was determined and fitted to an empirical equation. The release of drug from drug-loaded nanospheres dispersing in a conventional cream was evaluated. A comparative in vitro diffusion study was carried out between a commercial brand of cream and the cream incorporating nanospheres.

**Results:** Formulation of nanospheres of betamethazone by a modified method produced discrete particles. Studies on drug:polymer ratio showed a linear relationship between drug concentration and percentage of loading. The in vitro release of drug-loaded nanospheres was found to be first order. The comparative in vitro diffusion study between the commercial cream and the formulated cream showed a marked reduction in release rate from nanospheres-bound cream.

**Conclusion:** Formulated topical cream containing nanospheres of betamethazone was found to be a potential dermal delivery system for sustaining the release of the drug.

**Keywords:** Nanospheres, desolvation and cross-linking method, ethyl cellulose, betamethazone, in-vitro diffusion studies.

*Corresponding Author. Tel: 91-423-2443393. Fax: 91-423-2442937. Email: dnvooty@sify.com
Introduction

In recent years, there has been a considerable interest in the development of novel drug delivery systems in order to modify and control pharmacokinetic behavior of the drugs. By incorporation into a carrier system, it is possible to alter the therapeutic index and duration of activity of drugs. Colloidal drug delivery system represents one of the frontiers of science, which offers numerous advantages such as improved efficiency, reduced toxicity and improved patient compliance over conventional dosage forms. Nanoparticles are colloidal drug delivery systems that offer site-specific as well as controlled drug delivery. Many of the conventional vehicles such as creams, ointments requires high concentration of active ingredients for effective therapy due to their low efficiency as delivery systems. Over the past decade, particulate carriers such as liposomes and microspheres have been investigated for the delivery of drugs to specific skin compartments in order to control drug input, release, retention and action in/into the skin and also to reduce systemic absorption and consequently adverse reactions. In vitro and in vivo experiments proved particulate carriers to be worthwhile for increasing cutaneous bioavailability and decreasing systemic absorption of many drugs. The topical bioavailability of 5-aminolevulinic acid was improved when loaded into liposomes. Incorporation of corticosteroids in liposomes provided a higher concentration and efficient delivery of corticosteroids. Hence, in the present study, an attempt has been made to formulate ethyl cellulose nanospheres containing betamethazone, which may provide prolonged drug delivery in the treatment of inflammation and also minimize side effects such as pruritis, hypertrichosis and erythema.

Experimental

Materials

Betamethazone (Glaxo SmithKline Pharmaceuticals Ltd), Ethyl cellulose (Sigma), Tripolydine phosphate (Sigma Chemicals), dialysis membrane (Sigma Chemicals), sodium hydroxide (LR grade), linseed oil (commercial grade), Tween 80 (LR grade, SD Fine Chemicals), toluene and potassium dihydrogen phosphate (LR grade, S.D Fine Chemicals) and ethanol (AR grade) were used.

Methods

Preparation of betamethazone nanospheres by desolvation and crosslinking method and study on drug : polymer ratio

An ethanolic solution (50 ml) containing betamethazone 6.25 mg, ethyl cellulose (1% w/v) and Tween 80 (1% w/v) was desolvated by stirring at 200 rpm at 30±1 ºC using distilled water. The extent of desolvation was monitored by visually by its turbid appearance and through optical microscopy. By trial and error method, it was determined that for every 50 ml of ethanolic solutions of ethyl cellulose, a minimum of 12 ml of water is required for desolvation. Tripolydine phosphate (10 ml of 15%) was added slowly to the suspension and stirred and continuously for 1 hr. The resultant turbid dispersion was dried at 30±1 ºC on a glass plate. Ethyl cellulose nanospheres, along with the impurities, were obtained as a powder mass. Water (5 ml) was added and centrifuged at 5000 rpm for 10 min. After washing with water, the nanospheres were collected in the supernatant layer as a thin ring-like structure, filtered and dried. For the determination of drug loading in each batch only the concentration of the drug was varied but other processing variables were kept constant.

Estimation of amount of drug incorporated into ethyl cellulose nanospheres

A quantity of drug-loaded nanospheres equivalent to 20 mg of drug from each batch placed in a mortar, 10 ml ethanol was added and triturated to crush the nanoparticles. This
solution was then centrifuged and the drug content of the supernatant solution was analyzed by UV spectrophotometry at 267.6 nm.

**Determination of particle size by transmission electron microscopy**

The size and shape of the particles were also examined using TEM (Jeol EX 12, Japan). The specimens were prepared by dropping a mixture of phosphotungstic acid a dilute suspension of the nanospheres on EM grids (Formvar filmed, G200 mesh, Bio Rad, UK). Each grid was held for 20 s horizontally and then 45 °C to allow excess fluid to drain. The specimens were air dried before examination with an electron microscope. The electron microscopic view of nanospheres containing betamethazone is shown in Fig 1.

**In vitro release of drug loaded nanospheres before incorporating into cream base**

A quantity of nanospheres equivalent to 20mg of drug from each batch was placed in a 250 ml conical flask and to it 20ml ethanol and 80 ml phosphate buffer pH 7.4 were added. The flask was kept in a shaker incubator with the shaker oscillating at 20/min at 37 °C. 5ml of drug release medium was withdrawn at various time intervals over a 24 h period. The samples were filtered and the drug content was analyzed by UV spectrophotometry at 267.6 nm.

**Invitro release of drug-loaded nanospheres after incorporation into cream**

10mg of drug-loaded nanospheres from each batch 'D' were placed in 250 ml conical flask, and 10 ml of ethanol and 90 ml of phosphate buffer saline (pH 7.4) was added to it. The flask was kept in a shaker incubator oscillating at 20/min at 37 ± 1°C. 5ml of drug release medium was withdrawn at various time intervals over a 24 h period. These samples were vacuum-filtered through a membrane of 1µm pore size. The drug content was determined spectrophotometrically at 267.6 nm.

**Formulation of conventional cream and dispersion of drug loaded nanospheres in cream**

**Preparation of creams**: Oil soluble ingredients from the formula were first dissolved in the oil phase and the water soluble ingredients were dissolved in the aqueous phase. Both the phases were prepared separately and heated to a temperature of 70 °C separately. The oil phase was slowly incorporated into the aqueous phase by vigorous stirring until the formation of cream was smooth and uniform. The formulated cream was investigated for its physical parameters like consistency, homogenicity, spreadability, washability and extrudability.

---

**Table 1**: Formula for preparing creams

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>For 100 g (w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stearic acid</td>
<td>18g</td>
</tr>
<tr>
<td>Glycerine</td>
<td>3g</td>
</tr>
<tr>
<td>Lanolin</td>
<td>2g</td>
</tr>
<tr>
<td>Triethanolamine</td>
<td>10g</td>
</tr>
<tr>
<td>Preservative</td>
<td>1 g</td>
</tr>
<tr>
<td>Perfume</td>
<td>q.s</td>
</tr>
<tr>
<td>Water</td>
<td>80mL</td>
</tr>
</tbody>
</table>

---

*Venkatesh et al*
Dispersion of drug loaded nanospheres into the cream base: A specific quantity of nanospheres from batch ‘D’ equivalent to 1mg of drug was incorporated into the selected cream base by simple mixing.

The medicated creams were then subjected to *invitro* diffusion studies. Three such sample batches were studied for their *in vitro* release characteristics.

**In vitro diffusion studies of the cream containing dispersed nanospheres:** Release of the drug, betamethazone, from the medicated creams was studied employing the permeation apparatus designed and described by *Fites et al.*\(^{14}\). A glass cylinder with both ends open (10 cm high 3.7 cm outer diameter) was used as the permeation cell. A dialysis tubing (Sigma) soaked in a mixture glycerin and water (1:1) for 2 hr before use was fixed to one end of the cylinder with the aid of an adhesive resulting in a permeation cell. The medicated cream (1 g) was placed in the cell (donor compartment) and the cell was immersed in a 250 ml beaker containing drug-free diffusion medium, i.e., a mixture of 20 ml of ethanol and 180 ml 7.4 pH phosphate buffer; which served as the receptor compartment. The cell was immersed to a depth of 1 cm below the surface of water in the receptor compartment. The medium in the receptor compartment was agitated using a magnetic stirrer at 37°C ± 1°C. A sample (5ml) of the receptor compartment fluid was taken at various intervals of time over a period of 24 h and analyzed for drug content at 267.6 nm. The volume withdrawn each time was replaced with drug-free receptor fluid. The amount of drug released at various intervals of time was calculated and plotted against time as shown in Fig 2. This procedure was repeated for the conventional cream (Betnovate cream betamethazone 0.1% w/w). The experiment was carried out in triplicate, and the mean cumulative percentage release from three batches was calculated.

**Results and Discussion**

The nanospheres prepared by desolvation and crosslinking method were found to have discrete particle size and shape within the size range of 703±11 nm. The TEM of the drug-loaded nanospheres is shown Fig.1. There was a linear relationship between concentration of drug and percentage of loading up to a particular concentration (25mg/mg polymer). A decrease in drug loading was observed after that point due to the saturation capacity of polymer. The drug loading capacity of different batches are shown in Table 2. The drug loading was found to be 23.9±1.8%, 36.9±1.1%, 62.4±2.0%, 74.0±0.2% and 20.9±1.4% respectively for batches A, B, C, D and E. In order to predict and correlate the release behavior of drugs from matrix, it is necessary to fit the data into a suitable model. The percentage of release from the drug-loaded nanospheres was in the range of 74 to 96%. The *in vitro* release profile of betamethazone from all the formulated batches are shown in Fig 2. Hence, the dissolution data were fitted according to the well known exponential equation,\(^{15}\) which is often used to describe drug release behavior from polymeric system.

\[
\frac{M_t}{M_{\infty}} = K t^n
\]
where, \( M_t / M_\infty \) is the fractional release of the drug, ‘t’ is the release time, ‘k’ is a constant which incorporated the properties of the macromolecular polymeric system and ‘n’ is the release exponent indicative of the mechanism of release. The ‘n’ value used for analysis of the drug release mechanism from the nanospheres was determined from log \((M_t / M_\infty)\) Vs log(t) plots. To calculate the release constant ‘k’, the logarithm of the remaining betamethazone in nanospheres is plotted versus time. The betamethazone nanospheres followed 1\(^{st}\) order release over the period. In Table 3, the values of ‘k’, ‘n’ and ‘r’ for five different batches as reported, and the ‘n’ values were within 0.5122 to 0.5399, and the ‘n’ value for the nanospheres bound cream was also 0.5272. Thus the release mechanism is based on Fickian diffusion for both the nanospheres and the nanosphere bound cream. Among the different batches of drug loaded nanospheres, batch ‘D’ (prepared with 25 mg of drug/mg polymer) was found to possess a comparatively better and higher drug loading capacity. Therefore, batch ‘C’ was subjected to TEM analysis and size of drug loaded nanospheres were found to be slightly higher than the plain nanospheres. Among the different

![Figure 3: Comparative in vitro drug release from conventional cream (■) and nanosphere-incorporated cream (♦) by dialysis method](image)

**Table 2: Betamethazone loading capacity of ethyl cellulose nanospheres**

<table>
<thead>
<tr>
<th>S. No</th>
<th>Formulation code</th>
<th>Drug concentration in polymer (mg/mg)</th>
<th>Drug loading capacity (%) ± SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Batch ‘A’</td>
<td>6.25</td>
<td>23.95±1.8</td>
</tr>
<tr>
<td>2</td>
<td>Batch ‘B’</td>
<td>12.5</td>
<td>36.95±1.1</td>
</tr>
<tr>
<td>3</td>
<td>Batch ‘C’</td>
<td>18.8</td>
<td>62.44±2.0</td>
</tr>
<tr>
<td>4</td>
<td>Batch ‘D’</td>
<td>25</td>
<td>73.99±0.2</td>
</tr>
<tr>
<td>5</td>
<td>Batch ‘E’</td>
<td>50</td>
<td>20.91±1.4</td>
</tr>
</tbody>
</table>

**Table 3: In vitro release kinetics of drug-loaded nanospheres**

<table>
<thead>
<tr>
<th>Formulation code</th>
<th>Drug concentration in polymer (mg/mg)</th>
<th>First order plot</th>
<th>Koresmeyer and Peppas</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>( k )</td>
<td>( r )</td>
</tr>
<tr>
<td>Batch ‘A’</td>
<td>6.25</td>
<td>0.0545</td>
<td>0.9947</td>
</tr>
<tr>
<td>Batch ‘B’</td>
<td>12.5</td>
<td>0.0469</td>
<td>0.9972</td>
</tr>
<tr>
<td>Batch ‘C’</td>
<td>18.8</td>
<td>0.0713</td>
<td>0.9789</td>
</tr>
<tr>
<td>Batch ‘D’</td>
<td>25</td>
<td>0.0794</td>
<td>0.9833</td>
</tr>
<tr>
<td>Batch ‘E’</td>
<td>50</td>
<td>0.0849</td>
<td>0.9924</td>
</tr>
<tr>
<td>Nanosphere-bound cream</td>
<td>0.0499</td>
<td>0.9993</td>
<td>0.5272</td>
</tr>
</tbody>
</table>

499  
batches of nanospheres containing betamethazone, batch ‘D’ prepared with 25 mg drug was incorporated into the cream. To compare the *in vitro* release profile of betamethazone from nanospheres after incorporation into the cream with that of drug release from conventional cream comparative *in vitro* diffusion study was carried out using phosphate buffer $\text{pH} 7.4$ containing 10% ethanol by dialysis method for 24 h. The study revealed that the release of betamethazone from the conventional cream was found to be faster than from nanosphere bound cream. The cumulative release of drug from conventional cream at the 6th hour was 57%, while it was only 28% for the formulated cream. The T$_{50\%}$ of the drug was found to be 3 and 11 h, for the conventional and nanosphere-incorporated creams, respectively. The comparative *in vitro* results obtained using the dialysis method are depicted in Fig 3. Thus, the formulated cream containing nanospheres exhibited sustained release over a period of 24 h. Indicating that the dispersion of nanospheres in the cream base had a retarding effect on the release rate of the drug.

**Conclusion**

Formulation and evaluation of a topical drug delivery system containing betamethazone loaded nanospheres was found to be a potential and cost effective and sustained dermal delivery system in terms of particle size distribution, optimum drug loading capacity, and *in vitro* diffusion characteristics. The system induced prolonged drug release and could, therefore, produce some benefits such as reduction in total dose, frequency of administration, and dose-related systemic side effects.

**References**